Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Today: 27/07/2026 · FUTURE · Forthcoming · Viewed
Funding agency: Horizon Europe
Call: HORIZON-MISS-2027-02
Type of action: HORIZON-RIA HORIZON Research and Innovation Actions | Deadline model: single-stage | Planned opening: 10/02/2027 | Model Grant Agreement: HORIZON Lump Sum Grant
Supporting the implementation of the Cancer Mission through Research and Innovation Actions.
Budget total: 8000000.0 EUR | Budget per project: — EUR
Deadline: 21/09/2027 (421 days left) | Duration: — months | Funding intensity: —% | Type: research
Eligibility: entity types: research institution, public body; countries: EU countries
#cancer#medicine#biomarkers#clinical trials
HealthResearch & Development
Matching by organization
"Rule filter" means the score came from a hard eligibility/preference check, not the AI — if that reasoning looks wrong for a specific organization, use Override below to correct it by hand; the system's own score stays visible for comparison and is never silently replaced.
| Organization | Match % | Source | Rationale | Override |
|---|---|---|---|---|
| Novatex Solutions LTD | 0% | Rule filter |
Excluded by eligibility/preference filters: Org type 'SME' not among eligible en…Excluded by eligibility/preference filters: Org type 'SME' not among eligible entity types ['research institution', 'public body']. |
Override |
| European Centre for Emerging Competencies and Technologies | 0% | Rule filter |
Excluded by eligibility/preference filters: Org type 'non-profit' not among elig…Excluded by eligibility/preference filters: Org type 'non-profit' not among eligible entity types ['research institution', 'public body']. |
Override |